Trial Profile
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Adverse reactions; Therapeutic Use
- 07 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Jul 2024.
- 28 Mar 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology